Revvity, Inc. Faces Valuation Shift Amid Declining Sales and Rising Costs

Revvity, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in its evaluation. This revision reflects a shift in the company's valuation grade, which has transitioned from a previously attractive position to one now categorized as very expensive.
Key financial metrics indicate that Revvity's P/E ratio stands at 33, while its Price to Book Value is recorded at 1.42. The company’s EV to EBIT is noted at 30.33, and its EV to EBITDA is 15.29. Additionally, the EV to Sales ratio is 4.65, and the PEG ratio is 3.05. The dividend yield is relatively modest at 0.32%, and the latest Return on Capital Employed (ROCE) is 4.39%, alongside a Return on Equity (ROE) of 4.30%.

Long-term trends show a decline in net sales, with an annual growth rate of -1.23%, and operating profit has also seen a decrease of -2.67% over the past five years. The company has faced challenges, including a significant rise in raw material costs and a high debt-equity ratio of 31.52%.

This evaluation adjustment highlights the current market position of Revvity, Inc. and its financial standing within the industry.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.